Five things you need to know about prenatal testmaker Natera’s $175M IPO
Natera's lead product, its Panorama test, screens for fetal abnormalities, including Down syndrome, Edwards syndrome and Turner syndrome, as well as severe organ abnormalities and fetal viability.